Andre Tesainer Brunetto

Possui graduação em Medicina pela Pontifícia Universidade Católica do Rio Grande do Sul (2002) e Residência médica em Medicina Interna pelo Hospital de Clínicas de Porto Alegre (HCPA, 2004). Título de especialista em Oncologia Clínica pela Associação Médica Brasileira (AMB) e Sociedade Brasileira de Oncologia (SBC). Possui mestrado em Oncologia Básica, Clinica e Radioterapia - Universidade de Londres. Doutorado no programa de Ciências médicas (PPGCM) na Universidade Federal do Rio grande do Sul (UFRGS). Possui especialização em Oncologia (Clinical Fellowship 2005-2010) e desenvolvimento em novas drogas anticâncer no Drug Development Unit (Institute of Cancer Research UK) e no Royal Marsden Hospital. Atualmente atua como médico Oncologista Pesquisador e Coordenador científico do centro de pesquisa do Instituto do Câncer Infantil (ICI), RS, BR.

Informações coletadas do Lattes em 24/05/2023

Acadêmico

Formação acadêmica

Mestrado em Oncologia Basica, Clinica e Radioterapia

2008 - 2009

University of London
Título: Advanced colorectal cancer (ACRC) and phase I trials: an evidence based approach from referring physician to trial participation., Ano de Obtenção: 2009
Orientador: Professor Stan Kaye
Bolsista do(a): Institute of Cancer Research, ICR, Inglaterra. Palavras-chave: Estudos de fase 1.Grande área: Ciências da Saúde

Especialização - Residência médica

2003 - 2005

Hospital de Clínicas de Porto Alegre
Residência médica em: Clinica GeralNúmero do registro: . Bolsista do(a): Ministerio da Edicação e Cultura, MEC, Brasil.

Especialização em Título Especialista Cancerologia Clínica

2011 - 2011

Sociedade Brasileira Cancerologia
Título: nao aplicável

Especialização em Oncologia Clinica

2006 - 2010

Royal Marsden Hospital
Título: Especializaçao em Oncologia Clinica
Bolsista do(a): Institute of Cancer Research, ICR, Grã-Bretanha.

Aperfeiçoamento em Diploma em Oncologia

2007 - 2008

University of London
Título: Diploma em Oncologia. Ano de finalização: 2008

Aperfeiçoamento em Certificado em Oncologia Clinica

2006 - 2007

University of London
Título: Certificado em Oncologia Clinica. Ano de finalização: 2007

Graduação em Medicina

1997 - 2002

Pontifícia Universidade Católica do Rio Grande do Sul
Título: Monografia: Tumor markers in Clinical Practice
Orientador: Bernardo Garicochea

Formação complementar

2002 - 2002

Extensão universitária em Estagio curriclular em Oncologia Clinica. , Hospital de Clínicas de Porto Alegre, HCPA, Brasil.

2001 - 2001

Extensão universitária em Estagio curricular em Oncologia Pediatrica. , Hospital de Clínicas de Porto Alegre, HCPA, Brasil.

2001 - 2001

Extensão universitária em Estagio extra-curricular em Oncologia. , The Johns Hopkins Hospital, JHH, Estados Unidos.

2000 - 2000

Extensão universitária em Histocompatibility/hematopoietic cell identif.. , Lindsley F. Kimball Research, LFKR, Estados Unidos.

1999 - 1999

Extensão universitária em Estagio Curricular em Pneumologia. , Hopsital São Lucas PUC, HSL, Brasil.

Idiomas

Inglês

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Espanhol

Compreende Bem, Fala Razoavelmente, Lê Razoavelmente, Escreve Pouco.

Português

Compreende Bem, Fala Bem, Lê Bem, Escreve Bem.

Áreas de atuação

Grande área: Ciências da Saúde / Área: Medicina / Subárea: Oncologia.

Grande área: Ciências da Saúde / Área: Medicina / Subárea: Oncologia/Especialidade: Estudos de Phase 1 em Oncologia.

Grande área: Ciências da Saúde / Área: Medicina / Subárea: Oncologia/Especialidade: Estudos de Phase 2 em Oncologia.

Grande área: Ciências da Saúde / Área: Medicina / Subárea: Oncologia/Especialidade: Estudos de Phase 3 em Oncologia.

Grande área: Ciências da Saúde / Área: Medicina / Subárea: Clínica Médica.

Participação em eventos

Prostate Cancer forum. 2016. (Oficina).

Best of ASCO 2014. Participou com Chairman de sessão sobre Tumores geniturinários. 2014. (Congresso).

Conference on Lung Cancer.Coordenador sessão oncologia. 2014. (Encontro).

I Fórum de Coloproctologia do HED.O que muda em relação ao tratamento oncológico com a avaliação K-ras e BRAF?. 2014. (Simpósio).

Best of ASCO 2013. Palestrante câncer de prostata. 2013. (Congresso).

Preceptorships in oncology. 2012. (Oficina).

37 SAEF.Visão Multidisciplinar Farmacêutica no Câncer. 2011. (Simpósio).

37 Semana academica estudos farmaceuticos (SAEF).Visão Multidisciplinar farmaceutica do Câncer- diagnóstico. 2011. (Encontro).

American Society of Clinical Oncology (ASCO). 2011. (Congresso).

Highlights em Câncer de Próstata - CliniOnco. 2011. (Outra).

SICAD - Simpósio Internacional de Câncer do Aparelho Digestivo.Neoplasia Localizada de Cólon e Reto: Novas perspectivas. 2011. (Simpósio).

Best of American Society of Clinical Oncology (ASCO). Tumores do Sistema Nervoso Central. 2010. (Congresso).

Congresso Franco Brasileiro de Oncologia. Terapia Aduvante em Cancer Coloratal com cetuximab. 2010. (Congresso).

Palestrante no evento anual da liga de Neurologia.Manifestações Neurológicas de Doenças Sisêmicas. 2010. (Outra).

American Society of Clinical Oncology (ASCO) Annual Meeting. A first in human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. 2009. (Congresso).

Curso Advanced Life Support (ALS). 2009. (Outra).

ECCLU ? Educational Cancer Convention Lugano. Complications of anti-angiogenic therapy.. 2009. (Congresso).

European Society of Clinical Oncology (ESMO) Annual Meeting. Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach. 2009. (Congresso).

Institute of Cancer Research (ICR) Centenary Conference. Phase 1 treatment in advanced colorectal cancer (ACRC).. 2009. (Congresso).

National Cancer Research Institute (NCRI) Annual Conference. A first in human Phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumor activity.. 2009. (Congresso).

Best of American Society of Clinical Oncology (ASCO). Highlights em Sarcoma e Melanoma. 2008. (Congresso).

Curso de "Cardiopulmonary Resuscitation and Basic life Support. 2008. (Outra).

EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. A phase I clinical trial of Belinostat (PXD101) in combination with Doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS). 2008. (Congresso).

National Cancer Research Institute (NCRI) Annual Conference. The Royal Marsden Hospital (RMH) prognostic score for phase I studies.. 2008. (Congresso).

Curso de Good Clinical Practice (GCP). 2006. (Outra).

Curso dúvidas Comuns na Prática Clínica - PUCRS. 2002. (Outra).

Curso Tópicos em Epidemiologia - AMRIGS. 2002. (Outra).

Curso Tópicos em Medicina Intensiva - AMRIGS. 2002. (Outra).

Curso Tópicos em Medicina Interna I. 2002. (Outra).

5 Congressso sobre Tranplante de Medula Óssea e Hemopatias Malignas. 2001. (Congresso).

Curso de Extensão Universitária A Morte e o Morrer - PUCRS. 2001. (Outra).

Curso de Urgencia em Radiologia - PUCRS. 2001. (Outra).

II Curso de Urgencias em Gatroenterologia- PUCRS. 2001. (Outra).

Workshop em Embolia Pulmonar - PUCRS. 2001. (Oficina).

XII Congresso Brasileiro de Cirurgia Torácica. 2001. (Congresso).

17 Congresso da Associação Médica do Rio Grande do Sul. 2000. (Congresso).

Curso de Extensão em tópicos de Hematologia- Fundação Médica. 2000. (Outra).

II Congresso Gaúcho de Clinica Medica. 1999. (Congresso).

VI Jornada de Pneumologia - PUCRS. 1999. (Oficina).

XXIX Encontro científico dos estudantes de Medicina (ECEM). 1999. (Encontro).

Curso de Doenças Frequentes, Diagnóstico e Conduta - HCPA. 1998. (Outra).

Produções bibliográficas

FREIRE, NATÁLIA HOGETOP ; JAEGER, MARIANE DA CUNHA ; de Farias, Caroline Brunetto ; NÖR, CAROLINA ; SOUZA, BARBARA KUNZLER ; GREGIANIN, LAURO ; BRUNETTO, ANDRÉ TESAINER ; Roesler, Rafael . Targeting the epigenome of cancer stem cells in pediatric nervous system tumors. MOLECULAR AND CELLULAR BIOCHEMISTRY , v. 1, p. 1, 2023.
FRATINI, LIVIA ; DALMOLIN, MATHEUS GIBEKE SIQUEIRA ; SINIGAGLIA, MARIALVA ; DA SILVEIRA PERLA, ALEXANDRE ; de Farias, Caroline Brunetto ; BRUNETTO, ALGEMIR L. ; BRUNETTO, ANDRÉ T. ; DA CUNHA JAEGER, MARIANE ; Roesler, Rafael . ZEB1 is a Subgroup-Specific Marker of Prognosis and Potential Drug Target in Medulloblastoma. NEUROMOLECULAR MEDICINE , v. 5, p. 64, 2022.
Roesler, Rafael ; de Farias, Caroline Brunetto ; Brunetto, André T ; GREGIANIN, LAURO ; JAEGER, MARIANE ; NÖR, CAROLINA ; THOMAZ, AMANDA . Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma. NEURO-ONCOLOGY , v. 24, p. 1210-1211, 2022.
STEFANI, RODRIGO ROSA DE ; TONI, ELISA CRISTINA DE ; FARIAS, CAROLINE BRUNETTO DE ; BRUNETTO, ANDRÉ TESAINER ; Brunetto, Algemir Lunardi ; Roesler, Rafael ; ALHO, CLARICE SAMPAIO ; FRIEDRICH, DEISE CRISTINE . GGAA microsatellites of NR0B1 promoter region in Ewing's sarcoma patients and healthy individuals from a south Brazilian population. REVISTA BRASILEIRA DE CANCEROLOGIA , v. 68, p. 1, 2022.
SOUZA, BARBARA KUNZLER ; FREIRE, NATALIA HOGETOP ; JAEGER, MARIANE ; de Farias, Caroline Brunetto ; BRUNETTO, ALGEMIR L. ; BRUNETTO, ANDRÉ T. ; Roesler, Rafael . G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma. NEUROMOLECULAR MEDICINE , v. 24, p. 392-398, 2022.
FRATINI, LÍVIA ; JAEGER, MARIANE ; de Farias, Caroline Brunetto ; BRUNETTO, ANDRÉ T. ; BRUNETTO, ALGEMIR L. ; SHAW, LISA ; Roesler, Rafael . Oncogenic functions of ZEB1 in pediatric solid cancers: interplays with microRNAs and long noncoding RNAs. MOLECULAR AND CELLULAR BIOCHEMISTRY , v. 1, p. 1-1, 2021.
CURRA, MARINA ; GABRIEL, AMANDA F. ; FERREIRA, MARIA BEATRIZ C. ; MARTINS, MARCO ANTONIO T. ; BRUNETTO, ANDRÉ T. ; GREGIANIN, LAURO J. ; MARTINS, MANOELA DOMINGUES . Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy. SUPPORTIVE CARE IN CANCER , v. 1, p. 1, 2021.
FARIAS GABRIEL, AMANDA ; SILVEIRA, FELIPE MARTINS ; CURRA, MARINA ; SCHUCH, LAUREN FRENZEL ; WAGNER, VIVIAN PETERSEN ; MARTINS, MARCO ANTONIO TREVIZANI ; SILVEIRA MATTE, URSULA ; SIEBERT, MARINA ; BOTTON, MARIANA RODRIGUES ; BRUNETTO, ANDRÉ TESAINER ; Gregianin, Lauro José ; MARTINS, MANOELA DOMINGUES . Risk factors associated with the development of oral mucositis in pediatric oncology patients: Systematic review and meta-analysis. ORAL DISEASES , v. 1, p. 1, 2021.
RIBEIRO-DANTAS, MARCEL DA CÂMARA ; OLIVEIRA IMPARATO, DANILO OLIVEIRA ; DALMOLIN, MATHEUS GIBEKE SIQUEIRA ; de Farias, Caroline Brunetto ; BRUNETTO, ANDRÉ TESAINER ; DA CUNHA JAEGER, MARIANE ; Roesler, Rafael ; SINIGAGLIA, MARIALVA ; SIQUEIRA DALMOLIN, RODRIGO JULIANI . Reverse Engineering of Ewing Sarcoma Regulatory Network Uncovers PAX7 and RUNX3 as Master Regulators Associated with Good Prognosis. Cancers , v. 13, p. 1860, 2021.
THOMAZ, AMANDA ; JAEGER, MARIANE ; BRUNETTO, ALGEMIR L. ; BRUNETTO, ANDRÉ T. ; GREGIANIN, LAURO ; de Farias, Caroline Brunetto ; RAMASWAMY, VIJAY ; NÖR, CAROLINA ; TAYLOR, MICHAEL D. ; Roesler, Rafael . Neurotrophin Signaling in Medulloblastoma. Cancers , v. 12, p. 2542, 2020.
PERLA, ALEXANDRE ; FRATINI, LÍVIA ; CARDOSO, PAULA S. ; NÖR, CAROLINA ; BRUNETTO, ANDRÉ T. ; BRUNETTO, ALGEMIR L. ; de Farias, Caroline Brunetto ; JAEGER, MARIANE ; Roesler, Rafael . Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY , v. 8, p. 1-1, 2020.
PINHEIRO, KELLY V. ; THOMAZ, AMANDA ; SOUZA, BÁRBARA KUNZLER ; METCALFE, VICTORIA ANNE ; FREIRE, NATÁLIA HOGETOP ; BRUNETTO, ANDRÉ TESAINER ; de Farias, Caroline Brunetto ; JAEGER, MARIANE ; BAMBINI, VICTORIO ; SMITH, CHRISTOPHER G. S. ; SHAW, LISA ; Roesler, Rafael . Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma. MOLECULAR BIOLOGY REPORTS , v. 47, p. 6817-6828, 2020.
DA CUNHA JAEGER, MARIANE ; GHISLENI, EDUARDA CHIESA ; CARDOSO, PAULA SCHOPRONI ; SINIGLAGLIA, MARIALVA ; FALCON, TIAGO ; BRUNETTO, ANDRÉ T. ; BRUNETTO, ALGEMIR L. ; de Farias, Caroline Brunetto ; TAYLOR, MICHAEL D. ; NÖR, CAROLINA ; RAMASWAMY, VIJAY ; Roesler, Rafael . HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. JOURNAL OF MOLECULAR NEUROSCIENCE , v. 70, p. 981-992, 2020.
CURRA, MARINA ; GABRIEL, AMANDA DE FARIAS ; MARTINS, MARCO ANTONIO TREVIZANI ; FERREIRA, MARIA BEATRIZ CARDOSO ; Brunetto, André ; Gregianin, Lauro José ; MARTINS, MANOELA DOMINGUES . RISK FACTORS ASSOCIATED WITH ORAL MUCOSITIS IN PEDIATRIC PATIENTS WITH CANCER. Oral Surgery Oral Medicine Oral Pathology Oral Radiology , v. 130, p. e279, 2020.
ANTUNES, BRUNO PEREIRA ; BECKER, RICARDO GEHRKE ; BRUNETTO, ANDRÉ TESAINER ; PAVEI, BRUNO SILVEIRA ; DE-FARIAS, CAROLINE BRUNETTO ; RIVERO, LUÍS FERNANDO DA ROSA ; SANTOS, JULIE FRANCINE CERUTTI ; DE-OLIVEIRA, BRUNA MEDEIROS ; Gregianin, Lauro José ; Roesler, Rafael ; Brunetto, Algemir Lunardi ; PAGNUSSATO, FERNANDO ; GALIA, CARLOS ROBERTO . Expressão de neurotrofinas e de seus receptores no osteossarcoma primário.. REVISTA DO COLÉGIO BRASILEIRO DE CIRURGIÕES (ONLINE) , v. 46, p. e2094, 2019.
BUENDIA DUQUE, MARIENELA ; PINHEIRO, KELLY DE VARGAS ; THOMAZ, AMANDA ; DA SILVA, CAMILA ALVES ; FREIRE, NATÁLIA HOGETOP ; BRUNETTO, ANDRÉ TESAINER ; Schwartsmann, Gilberto ; JAEGER, MARIANE ; de Farias, Caroline Brunetto ; Roesler, Rafael . Combined Inhibition of HDAC and EGFR Reduces Viability and Proliferation and Enhances STAT3 mRNA Expression in Glioblastoma Cells. JOURNAL OF MOLECULAR NEUROSCIENCE , v. 1, p. 49-57, 2019.
THOMAZ, AMANDA ; PINHEIRO, KELLY DE VARGAS ; SOUZA, BÁRBARA KUNZLER ; GREGIANIN, LAURO ; BRUNETTO, ALGEMIR L. ; BRUNETTO, ANDRÉ T. ; de Farias, Caroline Brunetto ; JAEGER, MARIANE DA CUNHA ; RAMASWAMY, VIJAY ; NÖR, CAROLINA ; TAYLOR, MICHAEL D. ; Roesler, Rafael . Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma. Frontiers in Pharmacology , v. 10, p. 1-1, 2019.
VAN DER NOLL, RUUD ; JAGER, AGNES ; Ang, Joo Ern ; MARCHETTI, SERENA ; MERGUI-ROELVINK, MARJA W. J. ; LOLKEMA, MARTIJN P. ; DE JONGE, MAJA J. A. ; VAN DER BIESSEN, DIANE A. ; Brunetto, Andre T. ; Arkenau, Hendrik-Tobias ; TCHAKOV, ILIAN ; BEIJNEN, JOS H. ; DE BONO, JOHANN S. ; SCHELLENS, JAN H. M. . Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1). INVESTIGATIONAL NEW DRUGS , v. 1, p. 1-12, 2019.
VAN DER NOLL, RUUD ; JAGER, AGNES ; Ang, Joo Ern ; MARCHETTI, SERENA ; MERGUI-ROELVINK, MARJA W. J. ; DE BONO, JOHANN S. ; LOLKEMA, MARTIJN P. ; DE JONGE, MAJA J. A. ; VAN DER BIESSEN, DIANE A. ; Brunetto, Andre T. ; Arkenau, Hendrik-Tobias ; TCHAKOV, ILIAN ; BEIJNEN, JOS H. ; DE GRÈVE, JACQUES ; SCHELLENS, JAN H. M. . Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). INVESTIGATIONAL NEW DRUGS , v. 1, p. 1-12, 2019.
SOUZA, BÁRBARA KUNZLER ; DA COSTA LOPEZ, PATRÍCIA LUCIANA ; MENEGOTTO, PÂMELA ROSSI ; VIEIRA, IGOR ARAUJO ; KERSTING, NATHALIA ; ABUJAMRA, ANA LÚCIA ; BRUNETTO, ANDRÉ T. ; BRUNETTO, ALGEMIR L. ; GREGIANIN, LAURO ; de Farias, Caroline Brunetto ; THIELE, CAROL J. ; Roesler, Rafael . Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. MOLECULAR NEUROBIOLOGY , v. 1, p. 1-17, 2018.
HORBACH, LEONARDO ; SINIGAGLIA, MARIALVA ; DA SILVA, CAMILA ; OLGUINS, DANIELLY ; GREGIANIN, LAURO ; BRUNETTO, ALGEMIR ; BRUNETTO, ANDRÏ' ; Roesler, Rafael ; DE FARIAS, CAROLINE . Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. MOLECULAR AND CLINICAL ONCOLOGY , v. 8, p. 719-724, 2018.
HEINEN, TIAGO ELIAS ; SANTOS, RAFAEL PEREIRA DOS ; ROCHA, AMANDA DA ; SANTOS, MICHEL PINHEIRO DO ; LOPEZ, PATRÍCIA LUCIANA DA COSTA ; FILHO, MARCO AURÉLIO SILVA ; SOUZA, BÁRBARA KUNZLER ; RIVERO, LUÍS FERNANDO DA ROSA ; BECKER, RICARDO GEHRKE ; Gregianin, Lauro José ; Brunetto, Algemir Lunardi ; BRUNETTO, ANDRÉ TESAINER ; FARIAS, CAROLINE BRUNETTO DE ; Roesler, Rafael . Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma. OncoTarget , v. 23, p. 34860-80, 2016.
PORTICH, JÚLIA PLENTZ ; GIL, MIRELA SEVERO ; DOS SANTOS, RAFAEL PEREIRA ; GOULART, BRUNO KILPP ; FERREIRA, MARIA BEATRIZ CARDOSO ; LOSS, JISEH FAGUNDES ; Gregianin, Lauro José ; Brunetto, Algemir Lunardi ; BRUNETTO, ANDRÉ TESAINER ; Roesler, Rafael ; de Farias, Caroline Brunetto . Low brain-derived neurotrophic factor levels are associated with active disease and poor prognosis in childhood acute leukemia. Cancer Biomarkers , v. 17, p. 347-352, 2016.
ALMEIDA, VIVIANE RÖSNER ; VIEIRA, IGOR ARAUJO ; BUENDIA, MARIENELA ; BRUNETTO, ANDRÉ TESAINER ; GREGIANIN, LAURO J. ; Brunetto, Algemir Lunardi ; KLAMT, FÁBIO ; de Farias, Caroline Brunetto ; Abujamra, Ana Lucia ; LOPEZ, PATRÍCIA LUCIANA DA COSTA ; Roesler, Rafael . Combined Treatments with a Retinoid Receptor Agonist and Epigenetic Modulators in Human Neuroblastoma Cells. Molecular Neurobiology , v. 00, p. 00, 2016.
JAEGER, MARIANE ; GHISLENI, EDUARDA C. ; FRATINI, LÍVIA ; BRUNETTO, ALGEMIR L. ; Gregianin, Lauro José ; BRUNETTO, ANDRÉ T. ; Schwartsmann, Gilberto ; DE FARIAS, CAROLINE B. ; Roesler, Rafael . Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists. Child's Nervous System (Print) , v. 32, p. 61, 2015.
THOMAZ, AMANDA ; JAEGER, MARIANE ; BUENDIA, MARIENELA ; BAMBINI-JUNIOR, VICTORIO ; Gregianin, Lauro José ; Brunetto, Algemir Lunardi ; BRUNETTO, ANDRÉ T. ; de Farias, Caroline Brunetto ; Roesler, Rafael . BDNF/TrkB Signaling as a Potential Novel Target in Pediatric Brain Tumors: Anticancer Activity of Selective TrkB Inhibition in Medulloblastoma Cells. Journal of Molecular Neuroscience , v. 8, p. 1, 2015.
Mattei, Jane ; ACHCAR, ROSANE D. ; CANO, CARLOS H. ; MACEDO, BRUNO R. ; MEURER, LUISE ; BATLLE, BRENDA S. ; GROSHONG, STEVE D. ; KULCZYNSKI, JANE M. ; Roesler, Rafael ; DAL LAGO, LISSANDRA ; Brunetto, Andre T. ; Schwartsmann, Gilberto . Gastrin-Releasing Peptide Receptor Expression in Lung Cancer. Archives of Pathology & Laboratory Medicine (1976) , v. 138, p. 98-104, 2014.
MOLIFE, L. R. ; DEAN, E. J. ; Blanco-Codesido, M. ; KREBS, M. G. ; BRUNETTO, A. T. ; GREYSTOKE, A. P. ; DANIELE, G. ; LEE, L. ; KUZNETSOV, G. ; MYINT, K. T. ; WOOD, K. ; DE LAS HERAS, B. ; RANSON, M. R. . A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors. Clinical Cancer Research (Print) , v. 20, p. 6284-6294, 2014.
MORENO GARCIA, V. ; Olmos, D. ; Gomez-Roca, C. ; CASSIER, P. A. ; MORALES-BARRERA, R. ; del Conte, G. ; Gallerani, E. ; BRUNETTO, A. T. ; Schoffski, P. ; Marsoni, S. ; SCHELLENS, J. H. M. ; Penel, N. ; VOEST, E. ; EVANS, J. ; Plummer, R. ; WILSON, R. H. ; SORIA, J. C. ; Tabernero, J. ; Verweij, J. ; Kaye, S. B. . Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. Clinical Cancer Research (Print) , v. 20, p. 5663-5671, 2014.
BRUNETTO, A. T. ; Ang, J. E. ; Lal, R. ; Olmos, D. ; MOLIFE, L. R. ; Kristeleit, R. ; PARKER, A. ; CASAMAYOR, I. ; OLALEYE, M. ; Mais, A. ; Hauns, B. ; STROBEL, V. ; Hentsch, B. ; de Bono, J. S. . First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research (Print) , v. 19, p. 5494-5504, 2013.
Olmos, D. ; A&amp ; Marsoni, S. ; Morales, R. ; Gomez-Roca, C. ; Verweij, J. ; Voest, E. E. ; Schoffski, P. ; Ang, J. E. ; Penel, N. ; Schellens, J. H. ; del Conte, G. ; BRUNETTO, A. T. ; Evans, T. R. J. ; Wilson, R. ; Gallerani, E. ; Plummer, R. ; Tabernero, J. ; Soria, J.-C. ; Kaye, S. B. . Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. Journal of Clinical Oncology , v. 30, p. 996-1004, 2012.
DOS SANTOS, L. V. ; SOUZA, F. H. ; BRUNETTO, A. T. ; SASSE, A. D. ; DA SILVEIRA NOGUEIRA LIMA, J. P. . Neurokinin-1 Receptor Antagonists for Chemotherapy-Induced Nausea and Vomiting: A Systematic Review. Journal of the National Cancer Institute (Print) , v. 104, p. 1280-1292, 2012.
Messiou, C. ; ORTON, M. ; Ang, J. E. ; COLLINS, D. J. ; MORGAN, V. A. ; MEARS, D. ; CASTELLANO, I. ; PAPADATOS-PASTOS, D. ; Brunetto, A. ; Tunariu, N. ; MANN, H. ; TESSIER, J. ; YOUNG, H. ; GHIORGHIU, D. ; MARLEY, S. ; Kaye, S. B. ; DEBONO, J. S. ; Leach, M. O. ; deSouza, N. M. . Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. Radiology , v. 265, p. 426-436, 2012.
Abujamra, Ana Lucia ; DALL'IGNA, CELSO ; Coradini, Patrícia ; Manica, Denise ; Brunetto, André ; Escosteguy, Juliana Ribas ; Cigana, Luciana Facchini ; Gregianin, Lauro José . The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatric Blood & Cancer , v. na, p. n/a-n/a, 2012.
Yap, T. A. ; Olmos, D. ; BRUNETTO, A. T. ; Tunariu, N. ; Barriuso, J. ; Riisnaes, R. ; Pope, L. ; Clark, J. ; Futreal, A. ; Germuska, M. ; Collins, D. ; deSouza, N. M. ; Leach, M. O. ; Savage, R. E. ; Waghorne, C. ; Chai, F. ; Garmey, E. ; Schwartz, B. ; Kaye, S. B. ; de Bono, J. S. . Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. Journal of Clinical Oncology , v. 29, p. 1271-1279, 2011.
Olmos, D. ; Barker, D. ; Sharma, R. ; BRUNETTO, A. T. ; Yap, T. A. ; Taegtmeyer, A. B. ; Barriuso, J. ; Medani, H. ; Degenhardt, Y. Y. ; Allred, A. J. ; Smith, D. A. ; Murray, S. C. ; Lampkin, T. A. ; Dar, M. M. ; Wilson, R. ; de Bono, J. S. ; Blagden, S. P. . Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies. Clinical Cancer Research (Print) , v. 17, p. 3420-3430, 2011.
Petrarca, Cristiane Rios ; Brunetto, Andre T. ; Duval, Vinicius ; Brondani, Adriana ; Carvalho, Gisele Pereira ; Garicochea, Bernardo . Survivin As a Predictive Biomarker of Complete Pathologic Response to Neoadjuvant Chemotherapy in Patients With Stage II and Stage III Breast Cancer. Clinical Breast Cancer , v. 11, p. 129-134, 2011.
Brunetto, Andre ; Olmos, David ; Arkenau, Hendrik-Tobias ; Tan, Daniel ; Yap, Timomy ; de Bono, Johann ; Barriuso, Jorge ; Kaye, Stan . Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey. Journal of Oncology , v. 2011, p. 1-6, 2011.
Blanco Codesido, Montserrat ; Tesainer Brunetto, Andre ; Frentzas, Sophia ; Moreno Garcia, Victor ; Papadatos-Pastos, Dionysis ; Pedersen, Joanna Vitfell ; Trani, Leonardo ; Puglisi, Martina ; Molife, L. Rhoda ; Banerji, Udai . Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials. Oncology , v. 81, p. 135-140, 2011.
Brunetto, Andre Tesainer ; Roesler, Rafael ; Abujamra, Ana Lucia ; de Castro, Claudio Galvão ; Schwartsmann, Gilberto ; Brunetto, Algemir Lunardi . The process of drug development in pediatric oncology: a review of basic principals and a look into the future. Future Medicinal Chemistry , v. 1, p. 1237-1249, 2011.
Moreira Lima Gamboa, M. ; Tesainer Brunetto, A. ; Ferreira Dos Santos, M.E. ; Gregianin, L. . The pharmacists role in clinical research. Farmacia Hospitalaria , v. 35, p. 341-342, 2011.
Brunetto, A T ; Sarker, D ; Papadatos-Pastos, D ; Fehrmann, R ; Kaye, S B ; Johnston, S ; Allen, M ; De Bono, J S ; Swanton, C . A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. British Journal of Cancer , v. 103, p. 607-612, 2010.
Brunetto, Andre T. ; Carden, Craig P. ; Myerson, James ; Faria, Ana Luisa ; Ashley, Sue ; Popat, Sanjay ; O?Brien, Mary E. R. . Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of Thoracic Oncology , v. 5, p. 1397-1403, 2010.
Brunetto, Andre T. ; Ang, Joo Ern ; Olmos, David ; Tan, Daniel ; Barriuso, Jorge ; Arkenau, Hendrik-Tobias ; Yap, Timothy A. ; Molife, L. Rhoda ; Banerji, Udai ; de Bono, Johann . A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: Unplanned admissions as an early indicator of patient attrition?. European Journal of Cancer , v. 46, p. 2739-2745, 2010.
Roesler, Rafael ; Brunetto, André T ; Abujamra, Ana Lucia ; de Farias, Caroline Brunetto ; Brunetto, Algemir Lunardi ; Schwartsmann, Gilberto . Current and emerging molecular targets in glioma. Expert Review of Anticancer Therapy , v. 10, p. 1735-1751, 2010.
BRUNETTO, A. T. . O desenvolvimento de novas drogas contra o câncer- revisão e perspectivas futuras. Prática Hospitalar (Impresso) , v. 71, p. 8-14, 2010.
BRUNETTO, A. T. ; Kristeleit, Rebecca S ; de Bono, Johann S . Early oncology clinical trial design in the era of molecular-targeted agents. Future Oncology , v. 6, p. 1339-1352, 2010.
Arkenau, Hendrik-Tobias ; BRUNETTO, A. T. ; Barriuso, Jorge ; Olmos, David ; Eaton, David ; de Bono, Johann ; Judson, Ian ; Kaye, Stan . Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer. Oncology , v. 76, p. 151-156, 2009.
Yap, Timothy A ; BRUNETTO, A. T. ; Pandha, Hardev ; Harrington, Kevin ; de Bono, Johann S . Reovirus therapy in cancer: has the orphan virus found a home?. Expert Opinion on Investigational Drugs , v. 17, p. 1925-1935, 2008.
LEAL, F. ; Brunetto, Andre Tesainer ; MARTELETE, M. ; Schwartsmann, G. . Cancer. In: Bruce B. Duncan. (Org.). Medicina Ambulatorial: Condutas de Atenção Primária Baseadas em Evidências. 4ed.São Paulo: ARTmed, 2013, v. 1, p. 1040-1046.
Schwartsmann, Gilberto ; Brunetto, Andre T. . Evolution of Truth-Telling Practices in Brazil and South America. New Challenges in Communication with Cancer Patients. 1ed.: Springer US, 2013, v. , p. 419-428.
GENNARO,D ; BRUNETTO, A. T. ; et al. . Phase I dose-finding study of golvatinib (E7050), a c-Met and Eph receptor targeted multi-kinase inhibitor, administered orally QD to patients with advanced solid tumors. In: American Society of Clinical Oncology (ASCO), 2012, Chicago. Journal of Clinical Oncology, 2012. v. 30.
Ang, J.E. ; GARCIA, V. ; BRUNETTO, A. T. ; Papadatos-Pastos, D ; Arkenau, Hendrik-Tobias ; Blanco-Codesido, M. ; et al. . Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit.. In: ASCO, 2011, Boston. ASCO MEETING ABSTRACTS Jun 9, 2011:2555, 2011.
Blanco-Codesido, M. ; BRUNETTO, A. T. ; Frentzas,S. ; GARCIA, V. ; Papadatos-Pastos, D ; et al. . Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials. In: ASCO, 2011, Boston. ASCO MEETING ABSTRACTS Jun 9, 2011:8564.
CASSIER, P. ; GARCIA, V. ; Rocca, G. ; Olmos D. ; BRUNETTO, A. T. ; et al. . Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study. In: ASCO, 2011, Boston. ASCO MEETING ABSTRACTS Jun 9, 2011:3084, 2011.
Mattei, Jane ; Kat, Y. ; Roesler, R. ; BRUNETTO, A. T. ; et al. . Gastrin-releasing peptide receptor expression in Brazilian and Japanese patients with lung cancer and normal lung tissue samples from healthy individuals.. In: ASCO, 2011, Boston. ASCO MEETING ABSTRACTS Jun 9, 2011:10588, 2011.
BRUNETTO, A. T. ; Borges, G. ; Araújo, M.C. ; Filipe, G. ; Ribeiro, A. . Prognosis of patients with breast cancer (BC) in southern Brazil based on immunohistochemistry (IHC) and TNM staging.. In: ASCO, 2011, Boston. ASCO MEETING ABSTRACTS Jun 9, 2011:e12013, 2011.
Alam, S. ; Fehrmann, R ; Olmos D. ; Shah, K. ; Puglisi, M ; BRUNETTO, A. T. ; Postel-Viney, S. ; Baird, R. ; Molife, R. . Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience.. In: ASCO, 2010, Boston. Journal of Clinical Oncology, 2010. v. 28.
Blanco-Codesido, M. ; BRUNETTO, A. T. ; Frentzas,S. . Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. In: Joint ECCO 15 ? 34th ESMO Multidisciplinary Congress, 2010, Milan. Annals of Oncology, 2010. v. 21.
Ang, J.E. ; Clarkson-Jones, J.A. ; Swaisland, H. ; Brunetto, A.T. ; Lal, R. ; Farnsworth, A.P. ; Molife, L.R. ; Kaye, S.B. ; Carmichael, J. ; de Bono, J.S. . 405 A mass balance study to investigate the metabolism, excretion and pharmacokinetics of [14C]-olaparib (AZD2281) in patients with advanced solid tumours refractory to standard treatments. In: 22nd EORTC ? NCI?AACR Symposium on Molecular Targets and Cancer Therapeutics Programme and Abstract Book, 2010. European Journal of Cancer Supplements, 2010. v. 8. p. 128.
Papadatos-Pastos, D ; Blanco-Codesido, M. ; Carden, Craig P. ; Fehrmann, R ; Trani, L. ; Molife, R. ; BRUNETTO, A. T. ; Sandhu, S ; Massard, C. ; Banerji, Udai . Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.. In: ASCO, 2010, Boston. Journal of Clinical Oncology, 2010. v. 28.
BRUNETTO, A. T. ; Ang, J.E. ; Lal, R. ; Olmos D. ; Frentzas,S. ; Mais,A ; Hauns,B. ; Mollenhauer, M. ; Lahu,G. ; de Bono, Johann S . A first-in-human phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.. In: ASCO annual meeting, 2009, Orlando. Journal of Clinical Oncology, 2009. v. 27.
Olmos D. ; Alrred,R. ; Sharma, R ; BRUNETTO, A. T. ; Smith, D. ; Murray, S. ; Barker,D. ; Taegtmeyer,A. ; De Bono, J S ; Blagden,S. . Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. In: ASCO annual meeting, 2009, Orlando. Journal of Clinical Oncology, 2009. v. 27.
Tan, Daniel ; BRUNETTO, A. T. ; Ang, J.E. ; Olmos D. ; Barriuso, Jorge ; Frentzas,S. ; Arkenau, Hendrik-Tobias ; Yap, Timothy A ; de Bono J.S. . Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials.. In: ASCO annual meeting, 2009, Orlando. Journal of Clinical Oncology. v. 27.
Tolcher, A. ; Yap, Timothy A ; Fearen, A. ; Taylor,C. ; BRUNETTO, A. T. ; Beeram, M. ; Yan,L. ; de Bono J.S. . A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST).. In: ASCO annual meeting, 2009, Orlando. Journal of Clinical Oncology, 2010. v. 27.
BRUNETTO, A. T. ; Tan, D.S.W. ; Olmos, D. ; YAP, T. ; Frentzas, S. ; Sandhu, S. ; Denholm, K. ; Ayite, B. ; de Bono, J. ; Kaye, S. . 1258 Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach. In: ECCO 15 ? 34th ESMO Multidisciplinary Congress, 2009, Berlin. European Journal of Cancer. v. 7. p. 138-138.
YAP, T. ; Lolkema, M. ; Tanariu, N. ; Tan, D.S.W. ; BRUNETTO, A. T. ; Germuska,M. ; Garmey,E. ; Souza, N. ; de Bono J.S. . Pharmacokinetic and pharmacodynamic Phase I trial of ARQ 197 incorporating dynamic contrast-enhanced (DCE) and diffusion weighted (DW) magnetic resonance imaging (MRI) studies investigating the antiangiogenic and antitumor activity of selective cMet inhi. In: Joint ECCO 15 - 34TH ESMO, 2009, Berlin. European Journal of Cancer, 2009. v. 7. p. 121-121.
Olmos D. ; BRUNETTO, A. T. ; Ang, J.E. ; Tan, D.S.W. ; Sandhu, S ; Kristeleit, R. ; Forster, M. ; Molife, R. ; Kaye S.B. . Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials. In: Joint ECCO 15 - 34TH ESMO, 2009, Berlin. European Journal of Cancer, 2009. v. 7. p. 137-137.
Tan, D.S.W. ; BRUNETTO, A. T. ; YAP, T. ; Frentzas,S. ; Kaye S.B. . oral presentation gynaecological cancers. In: ECCLU - Educational Cancer Convention, 2009, Lugano. Annals of Oncology. v. 22.
BRUNETTO, A. T. ; Tan, D.S.W. ; YAP, T. ; Olmos D. ; Kaye S.B. . poster presentation gynaecological cancers. In: ECCLU - Educational Cancer Convention, 2009, Lugano. Annals of Oncology, 2009. v. 20.
Yap, Timothy A ; BRUNETTO, A. T. . First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC). In: Molecular Cancer Therapeutics 8, 2009, Boston. Molecular Cancer Therapeutics 8 (Meeting Abstract Supplement).
de Bono, J. ; Brunetto, A.T. ; Kristeleit, R. ; Mais, A. ; Hauns, B. ; Hentsch, B. . 1255 Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. In: ESMO, 2009, Berlin. European Journal of Cancer Supplements, 2009. v. 7.
BRUNETTO, A. T. ; CARDEN, C ; ASHLEY, S ; BAIRD, R ; MYERSON, J ; KRISTELEIT, R ; MONTES, A ; POPAT, S ; OBRIEN, M . Dose intensity in advanced non-small cell lung cancer. In: Bristish Thoracic Oncology Group (BTOG) meeting, 2008, Dublin. Lung Cancer. v. 60.
BRUNETTO, A. T. ; KRARUPHANSEN, A ; NIELSEN, O ; NORMAN, A ; SAFWAT, A ; TJORNELUND, J ; JUDSON, I . 420 POSTER A phase I clinical trial of belinostat (PXD101) in combination with doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS). In: 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics Programme, 2008, Geneva. European Journal of Cancer. v. 6. p. 132-132.
PAPADOPOULOS, P. ; BRUNETTO, A. T. ; Ashley, Sue ; Allen, M ; Smith, I. ; O?Brien, Mary E. R. . breast cancer, advanced. In: 33rd ESMO Congress, 2008, Stockholm. Annals of Oncology, 2008. v. 19.
Barriuso, Jorge ; Arkenau, Hendrik-Tobias ; Olmos D. ; Ang, J.E. ; Frentzas,S. ; BRUNETTO, A. T. ; Judson, I. ; de Bono J.S. ; Kaye S.B. . developmental therapeutics. In: 33rd ESMO Congress, 2008, Stockholm. Annals of Oncology, 2008. v. 19.
Ang, Joo Ern ; Co-autor ; Brunetto, A.T. . Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. 2011. (Apresentação de Trabalho/Congresso).
Blanco-Codesido, M. ; Co-autor ; Brunetto, A.T. . Clinical outcome of patients with metastasic melanoma undergoing phase I clinical trials.. 2011. (Apresentação de Trabalho/Congresso).
CASSIER, P. ; Co-autor ; Brunetto, A.T. . Dose-response relationship in phase I clinical trials: A European Drug Development Network (EDDN) collaboration study.. 2011. (Apresentação de Trabalho/Congresso).
Mattei, Jane ; Co-autor ; Brunetto, A.T. . Gastrin-releasing peptide receptor expression in Brazilian and Japanese patients with lung cancer and normal lung tissue samples from healthy individuals. 2011. (Apresentação de Trabalho/Congresso).
Alam, S. ; Co-autor ; BRUNETTO, A. T. . Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: A single-center experience. 2010. (Apresentação de Trabalho/Congresso).
Papadatos-Pastos, D ; Co-autor ; BRUNETTO, A. T. . Should patients with malignant intracranial space occupying lesions (M-ICSOLs) be excluded from phase I trials? The Royal Marsden Hospital Drug Development Unit experience.. 2010. (Apresentação de Trabalho/Congresso).
Tolcher, A. ; Co-autor ; BRUNETTO, A. T. . A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST). 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . A first in human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.. 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . Complications of Anti-angiogenic therapy. 2009. (Apresentação de Trabalho/Congresso).
Tan, D.S.W. ; Co-autor ; BRUNETTO, A. T. . BRCA1 positive ovarian cancer: A predisposition to therapeutic selectivity. 2009. (Apresentação de Trabalho/Congresso).
Tan, D.S.W. ; Co-autor ; BRUNETTO, A. T. . Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in Phase I trials. 2009. (Apresentação de Trabalho/Congresso).
Olmos D. ; Co-autor ; BRUNETTO, A. T. . Phase 1 first in human study of polo-like kinase selective inhibitor, GSK461364, in patients with advanced solid tumors. 2009. (Apresentação de Trabalho/Congresso).
Lolkema, M. ; Co-autor ; BRUNETTO, A. T. . Final results of Pharmacokinetic (PK) and pharmacodynamic (PD) Phase I trial of ARQ197 incorporating dynamic contrast-enhanced (DCE) and diffusion weighted (DW) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.. 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . Phase 1 treatment in advanced colorectal cancer (ACRC).. 2009. (Apresentação de Trabalho/Congresso).
de Bono J.S. ; Co-autor ; BRUNETTO, A. T. . Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor. 2009. (Apresentação de Trabalho/Congresso).
YAP, T. ; Co-autor ; BRUNETTO, A. T. . Pharmacokinetic (PK) and pharmacodynamic (PD) Phase I trial of ARQ197 incorporating dynamic contrast-enhanced (DCE) and diffusion weighted (DW) magnetic resonance imaging (MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition.. 2009. (Apresentação de Trabalho/Congresso).
De Bono, J S ; Co-autor ; BRUNETTO, A. T. . Clinical and preclinical development of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor.. 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach.. 2009. (Apresentação de Trabalho/Congresso).
Olmos D. ; Co-autor ; BRUNETTO, A. T. . Retrospective analysis of unplanned hospital admissions: an early surrogate indicator of patient (pt) attrition in phase-I trials. 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . A first in human Phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumor activity. 2009. (Apresentação de Trabalho/Congresso).
Frentzas,S. ; Co-autor ; BRUNETTO, A. T. . A study of melanoma patients in Phase I clinical trials: looking beyond the established. 2009. (Apresentação de Trabalho/Congresso).
Sarker, D ; Co-autor ; BRUNETTO, A. T. . Safety and feasibility of serial tumour biopsies in phase I clinical trials: the Royal Marsden Hospital Drug Development Unit experience. 2009. (Apresentação de Trabalho/Congresso).
Tan, D.S.W. ; Co-autor ; BRUNETTO, A. T. . A phase-I study of the combination of intravenous reovirus (REOLYSIN ) and gemcitabine in patients with advanced cancer.. 2009. (Apresentação de Trabalho/Congresso).
Kristeleit, R. ; Co-autor ; BRUNETTO, A. T. . A first-in-man, dose-escalating Phase I study of 4SC-201, a new oral histone deacetylase (HDAC) inhibitor in patients with advanced solid tumours. 2009. (Apresentação de Trabalho/Congresso).
Sandhu, S. ; Co-autor ; BRUNETTO, A. T. . Pharmacokinetic and pharmacodynamic phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. 2009. (Apresentação de Trabalho/Congresso).
Olmos D. ; Co-autor ; BRUNETTO, A. T. . Factores Prognosticos para la Supervivencia en Pacientes Incluidos en Ensayos Clinicos Fase-I.. 2009. (Apresentação de Trabalho/Congresso).
Henning, S.W. ; Co-autor ; BRUNETTO, A. T. . Preclinical and clinical development of resminostat, a new oral histone deacetylase (HDAC) inhibitor. 2009. (Apresentação de Trabalho/Congresso).
YAP, T. ; Co-autor ; BRUNETTO, A. T. . First in man, first in class, phase I study of MK-2206, an oral potent allosteric Akt inhibitor, in patients with advanced solid tumours. 2009. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . Dose-intensity in non-small cell lung cancer. 2008. (Apresentação de Trabalho/Congresso).
PAPADOPOULOS, P. ; Co-autor ; BRUNETTO, A. T. . The use of trastuzumab in metastatic breast cancer beyond disease progression. 2008. (Apresentação de Trabalho/Congresso).
Barriuso, Jorge ; Co-autor ; BRUNETTO, A. T. . Prospective validation of a prognostic score for patients treated in phase I trials.. 2008. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . The Royal Marsden Hospital (RMH) prognostic score for phase I studies. 2008. (Apresentação de Trabalho/Congresso).
Ang, J.E. ; Co-autor ; BRUNETTO, A. T. . First-in-man phase I trial of BYK408740, an oral HDAC inhibitor, in patients with advanced malignancies. 2008. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. . A phase I clinical trial of Belinostat (PXD101) in combination with Doxorubicin (BelDox) in advanced solid tumours, including soft tissue sarcomas (STS).. 2008. (Apresentação de Trabalho/Congresso).
Rech, A. ; Co-autor ; BRUNETTO, A. T. . Hodgkin Lymphoma in the Department of Pediatric Oncology. 2004. (Apresentação de Trabalho/Congresso).
Rech, A. ; Co-autor ; BRUNETTO, A. T. . Epidemiology of Non-hodgkin Lymphoma in the Department of Pediatric Oncology. 2001. (Apresentação de Trabalho/Congresso).
BRUNETTO, A. T. ; MARIANTE, A. ; Garicochea, B. . Febrile Neutropenia. Porto Alegre: EdiPUCRS, 2002 (Manual de Ùrgências Médicas- Faculdade de Medicina e Hospital São Lucas).
BRUNETTO, A. T. ; BRUNETTO, L. ; Garicochea, B. . Tumor Markers in Clinical Practice. Porto Alegre: EdiPUCRS, 2002 (Acta Medica - capitulo de livro).

Prêmios

2009

Merit award, American Society of Clinical Oncology (ASCO).

2009

Travel award, European Society of Clinical Oncology (ESMO) - ECCLU.

Histórico profissional

Endereço profissional

Instituto do Câncer Infantil do Rio Grande do Sul. , Rua São Manoel, Rio Branco, 90620110 - Porto Alegre, RS - Brasil, Telefone: (51) 33318704

Experiência profissional

2012 - 2018

Hospital Ernesto Dornelles

Vínculo: Colaborador, Enquadramento Funcional: Membro Colaborador CEP-HED, Carga horária: 2

2011 - 2015

Hospital Ernesto Dornelles

Vínculo: Colaborador, Enquadramento Funcional: Médico e Pesquisador

2011 - 2014

Instituto de Câncer de Brasília

Vínculo: Celetista formal, Enquadramento Funcional: Médico pesquisdador

2010 - 2014

Instituto Kaplan de Oncologia

Vínculo: Celetista formal, Enquadramento Funcional: Medico Oncologista

2010 - 2014

Fundação Central Sul Americana para o Desenvol. de Drogas Anti-Câncer

Vínculo: Celetista formal, Enquadramento Funcional: Médico pesquisador

2009 - Atual

American Society of Clinical Oncology

Vínculo: Membro, Enquadramento Funcional: Membro

2008 - Atual

European Society of Clinical Oncology

Vínculo: Membro, Enquadramento Funcional: Membro

2009 - 2010

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow Renal and Melanoma, Carga horária: 10

Outras informações:
Supervisores: Martin Gore, Dr James Larkin and Dr Lisa Pickering

2008 - 2010

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow Phase 1 unit, Carga horária: 40

Outras informações:
Supervisores: Professor Stan Kaye, Dr Johann de-Bono and Dr Udai Banerji

2008 - 2009

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow Gynae and Sarcoma, Carga horária: 10

Outras informações:
Supervisores: Professor Stan Kaye and Professor Ian Judson

2007 - 2008

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow GI and Lymphoma, Carga horária: 40, Regime: Dedicação exclusiva.

Outras informações:
Supervisores: Professor David Cunningham and Dr Ian Chau

2007 - 2007

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow Lung Unit, Carga horária: 40, Regime: Dedicação exclusiva.

Outras informações:
Supervisores: Dr Mary O?Brien and Dr Sanjay Popat.

2006 - 2006

Royal Marsden Hospital

Vínculo: Celetista formal, Enquadramento Funcional: Clinical Research Fellow Breast Unit, Carga horária: 40, Regime: Dedicação exclusiva.

Outras informações:
Supervisores: Professor Ian Smith and Dr Stephen Johnston

Atividades

06/2006 - 01/2010
Pesquisa e desenvolvimento, Department of Oncology.,Linhas de pesquisa

2014 - Atual

CLINIONCO

Vínculo: Colaborador, Enquadramento Funcional: Oncologista e pesquisador, Carga horária: 10

2015 - Atual

Instituto do Câncer Infantil do Rio Grande do Sul

Vínculo: Consultor contratado, Enquadramento Funcional: Coordenador Centro de Pesquisas, Carga horária: 20

2014 - Atual

Hospital Moinhos de Vento

Vínculo: Médico Oncologista, Enquadramento Funcional: Médico Colaborador, Carga horária: 6